Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation

We analyzed NMDA receptor subunit mRNAs, proteins, and anchoring proteins in mice transgenic for exon 1 of the HD gene. R6/2 mice had decreased levels of mRNAs encoding epsilon1 and epsilon2 NMDA receptor subunits (mouse orthologs of rat NR2A and NR2B subunits), but not the zeta1 subunit (mouse ortholog of NR1), as assessed by gene expression profiling and Northern blotting. In situ hybridization resolved mRNA decreases spatially to the CA1 field of hippocampus. Western blotting revealed decreases in plasma membrane-associated epsilon1 and epsilon2 subunits in hippocampus, and decreases in plasma membrane-associated zeta1 subunit in cortex and hippocampus. In addition, PSD-95 and alpha-actinin-2, proteins essential for anchoring NMDA receptors, were decreased. Finally, we found a decreased level of tyrosine-phosphorylated epsilon1 subunit, another determinant of NMDA receptor trafficking, in R6/2 hippocampus. Taken together, these data demonstrate multiple levels of NMDA receptor dysregulation, including abnormalities in mRNA expression levels, receptor stoichiometry, protein phosphorylation, and receptor trafficking.

[1]  Fabrice P Cordelières,et al.  The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. , 2002, Developmental cell.

[2]  Charles Kooperberg,et al.  Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. , 2002, Human molecular genetics.

[3]  C. Schwarz,et al.  Wild-Type and Mutant Huntingtins Function in Vesicle Trafficking in the Secretory and Endocytic Pathways , 1998, Experimental Neurology.

[4]  M. Chesselet,et al.  Decrease in Striatal Enkephalin mRNA in Mouse Models of Huntington’s Disease , 2000, Experimental Neurology.

[5]  S. Vicini,et al.  Characterization of NMDA Receptor Subunit‐Specific Antibodies: Distribution of NR2A and NR2B Receptor Subunits in Rat Brain and Ontogenic Profile in the Cerebellum , 1995, Journal of neurochemistry.

[6]  M. Hurlbert,et al.  Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. , 1999, Diabetes.

[7]  P. Reddy,et al.  Polyglutamine-expanded Huntingtin Promotes Sensitization of N-Methyl-d-aspartate Receptors via Post-synaptic Density 95* , 2001, The Journal of Biological Chemistry.

[8]  J. Coyle,et al.  Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea , 1976, Nature.

[9]  R. Deth,et al.  SH3 Domain-dependent Association of Huntingtin with Epidermal Growth Factor Receptor Signaling Complexes* , 1997, The Journal of Biological Chemistry.

[10]  K. Fischbeck,et al.  CREB-binding protein sequestration by expanded polyglutamine. , 2000, Human molecular genetics.

[11]  D. Tagle,et al.  Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[12]  Mark Turmaine,et al.  Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation , 1997, Cell.

[13]  M. Hayden,et al.  The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[14]  D. Standaert,et al.  Dopamine D1 Receptor-Dependent Trafficking of Striatal NMDA Glutamate Receptors to the Postsynaptic Membrane , 2001, The Journal of Neuroscience.

[15]  A. Feinberg,et al.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. , 1983, Analytical biochemistry.

[16]  Elena Cattaneo,et al.  Loss of normal huntingtin function: new developments in Huntington's disease research , 2001, Trends in Neurosciences.

[17]  Carlos Cepeda,et al.  Enhanced sensitivity to N‐methyl‐D‐aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease , 1999, Journal of neuroscience research.

[18]  Jianhong Luo,et al.  Subunit composition of N-methyl-D-aspartate receptors in the central nervous system that contain the NR2D subunit. , 1998, Molecular pharmacology.

[19]  Ann Marie Craig,et al.  Competitive binding of α-actinin and calmodulin to the NMDA receptor , 1997, Nature.

[20]  C A Ross,et al.  Interference by Huntingtin and Atrophin-1 with CBP-Mediated Transcription Leading to Cellular Toxicity , 2001, Science.

[21]  H. Lehrach,et al.  SH3GL3 associates with the Huntingtin exon 1 protein and promotes the formation of polygln-containing protein aggregates. , 1998, Molecular cell.

[22]  S. W. Davies,et al.  Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[23]  C. Cepeda,et al.  NMDA receptor function in mouse models of Huntington disease , 2001, Journal of neuroscience research.

[24]  Masahiko Watanabe,et al.  Distinct distributions of five N‐methyl‐D‐aspartate receptor channel subunit mRNAs in the forebrain , 1993, The Journal of comparative neurology.

[25]  B. Morris,et al.  In situ hybridization protocols for the Brain , 1994 .

[26]  D. Surmeier,et al.  Coordinated Expression of Dopamine Receptors in Neostriatal Medium Spiny Neurons , 1996, The Journal of Neuroscience.

[27]  M. Sheng,et al.  Ligand-gated ion channel interactions with cytoskeletal and signaling proteins. , 2000, Annual review of physiology.

[28]  C A Ross,et al.  Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. , 2000, Human molecular genetics.

[29]  H. Robertson,et al.  Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington’s disease mice , 2000, Neuroscience.

[30]  Nahida Matta,et al.  CAG expansion affects the expression of mutant huntingtin in the Huntington's disease brain , 1995, Neuron.

[31]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[32]  J. Cha,et al.  Transcriptional dysregulation in Huntington’s disease , 2000, Trends in Neurosciences.

[33]  P. Greengard,et al.  Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[34]  A Weindl,et al.  Changes of NMDA Receptor Subunit (NR1, NR2B) and Glutamate Transporter (GLT1) mRNA Expression in Huntington's Disease—An In Situ Hybridization Study , 1997, Journal of neuropathology and experimental neurology.

[35]  R. Huganir,et al.  Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. , 2000, Molecular pharmacology.

[36]  D. Housman,et al.  Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila , 2001, Nature.

[37]  Peter S. Harper,et al.  Huntington's disease , 1991 .

[38]  D. Borchelt,et al.  Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. , 1999, Human molecular genetics.

[39]  A. Morton,et al.  Selective Discrimination Learning Impairments in Mice Expressing the Human Huntington's Disease Mutation , 1999, The Journal of Neuroscience.

[40]  Christian Rosenmund,et al.  Calcium-induced actin depolymerization reduces NMDA channel activity , 1993, Neuron.

[41]  S B Dunnett,et al.  Abnormal Synaptic Plasticity and Impaired Spatial Cognition in Mice Transgenic for Exon 1 of the Human Huntington's Disease Mutation , 2000, The Journal of Neuroscience.

[42]  Shihua Li,et al.  Cellular Defects and Altered Gene Expression in PC12 Cells Stably Expressing Mutant Huntingtin , 1999, The Journal of Neuroscience.

[43]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[44]  G P Bates,et al.  Loss of cortical and thalamic neuronal tenascin‐C expression in a transgenic mouse expressing exon 1 of the human Huntington disease gene , 2001, The Journal of comparative neurology.

[45]  J. Schiefer,et al.  Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington's disease: behavioral testing and impact of diabetes mellitus , 2001, Behavioural Brain Research.

[46]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[47]  Marian DiFiglia,et al.  Excitotoxic injury of the neostriatum: a model for Huntington's disease , 1990, Trends in Neurosciences.

[48]  J. B. Martin,et al.  Selective sparing of a class of striatal neurons in Huntington's disease. , 1985, Science.

[49]  O. Hansson,et al.  Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Jianhong Luo,et al.  The majority of N-methyl-D-aspartate receptor complexes in adult rat cerebral cortex contain at least three different subunits (NR1/NR2A/NR2B). , 1997, Molecular pharmacology.

[51]  S. W. Davies,et al.  Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[52]  K. Magnusson.  Declines in mRNA Expression of Different Subunits May Account for Differential Effects of Aging on Agonist and Antagonist Binding to the NMDA Receptor , 2000, The Journal of Neuroscience.

[53]  A. Morton,et al.  Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene , 2000, Movement disorders : official journal of the Movement Disorder Society.

[54]  P. Seeburg,et al.  Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95. , 1995, Science.

[55]  Claire-Anne Gutekunst,et al.  A YAC Mouse Model for Huntington’s Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxicity, and Selective Striatal Neurodegeneration , 1999, Neuron.

[56]  L. Raymond,et al.  Increased Sensitivity to N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity in a Mouse Model of Huntington's Disease , 2002, Neuron.

[57]  Michael R. Hayden,et al.  Mutant Huntingtin Enhances Excitotoxic Cell Death , 2001, Molecular and Cellular Neuroscience.

[58]  S. Augood,et al.  Non-radioactive in situ hybridization using alkaline phosphatase-labelled oligonucleotides. , 2002, International review of neurobiology.

[59]  I. Kanazawa,et al.  Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription , 2000, Nature Genetics.

[60]  Joseph B. Martin,et al.  Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid , 1986, Nature.

[61]  R. Morris,et al.  Enhanced long-term potentiation and impaired learning in mice with mutant postsynaptic density-95 protein , 1998, Nature.